BR112018001615A2 - sistema de distribuição transdérmico - Google Patents
sistema de distribuição transdérmicoInfo
- Publication number
- BR112018001615A2 BR112018001615A2 BR112018001615A BR112018001615A BR112018001615A2 BR 112018001615 A2 BR112018001615 A2 BR 112018001615A2 BR 112018001615 A BR112018001615 A BR 112018001615A BR 112018001615 A BR112018001615 A BR 112018001615A BR 112018001615 A2 BR112018001615 A2 BR 112018001615A2
- Authority
- BR
- Brazil
- Prior art keywords
- hours
- dihydroetorphine
- less
- transdermal delivery
- delivery system
- Prior art date
Links
- 230000037317 transdermal delivery Effects 0.000 title abstract 2
- BRTSNYPDACNMIP-FAWZKKEFSA-N dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513441.4A GB201513441D0 (en) | 2015-07-30 | 2015-07-30 | Transdermal delivery system |
| PCT/GB2016/052307 WO2017017452A1 (en) | 2015-07-30 | 2016-07-28 | Transdermal delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018001615A2 true BR112018001615A2 (pt) | 2018-09-18 |
Family
ID=54062902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018001615A BR112018001615A2 (pt) | 2015-07-30 | 2016-07-28 | sistema de distribuição transdérmico |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180221299A1 (enExample) |
| EP (1) | EP3328431A1 (enExample) |
| JP (1) | JP2018528175A (enExample) |
| KR (1) | KR20180035859A (enExample) |
| CN (1) | CN108025077A (enExample) |
| AR (1) | AR105533A1 (enExample) |
| AU (1) | AU2016298761A1 (enExample) |
| BR (1) | BR112018001615A2 (enExample) |
| CA (1) | CA2994103A1 (enExample) |
| GB (1) | GB201513441D0 (enExample) |
| IL (1) | IL256995A (enExample) |
| MA (1) | MA42521A (enExample) |
| MX (1) | MX2018001318A (enExample) |
| SG (1) | SG10201913254RA (enExample) |
| TW (1) | TW201713340A (enExample) |
| WO (1) | WO2017017452A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10231248A (ja) * | 1997-02-19 | 1998-09-02 | T T S Gijutsu Kenkyusho:Kk | ジヒドロエトルフィン含有経皮吸収型製剤 |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| CL2004000927A1 (es) * | 2003-04-30 | 2005-01-28 | Purdue Pharma Lp | Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal. |
| TWI541246B (zh) * | 2008-12-08 | 2016-07-11 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
-
2015
- 2015-07-30 GB GBGB1513441.4A patent/GB201513441D0/en not_active Ceased
-
2016
- 2016-07-28 MA MA042521A patent/MA42521A/fr unknown
- 2016-07-28 EP EP16747572.2A patent/EP3328431A1/en not_active Withdrawn
- 2016-07-28 JP JP2018504666A patent/JP2018528175A/ja active Pending
- 2016-07-28 CA CA2994103A patent/CA2994103A1/en not_active Abandoned
- 2016-07-28 AU AU2016298761A patent/AU2016298761A1/en not_active Abandoned
- 2016-07-28 SG SG10201913254RA patent/SG10201913254RA/en unknown
- 2016-07-28 WO PCT/GB2016/052307 patent/WO2017017452A1/en not_active Ceased
- 2016-07-28 BR BR112018001615A patent/BR112018001615A2/pt not_active IP Right Cessation
- 2016-07-28 MX MX2018001318A patent/MX2018001318A/es unknown
- 2016-07-28 US US15/748,548 patent/US20180221299A1/en not_active Abandoned
- 2016-07-28 KR KR1020187005833A patent/KR20180035859A/ko not_active Withdrawn
- 2016-07-28 CN CN201680054263.8A patent/CN108025077A/zh active Pending
- 2016-07-29 AR ARP160102318A patent/AR105533A1/es unknown
- 2016-07-29 TW TW105124084A patent/TW201713340A/zh unknown
-
2018
- 2018-01-18 IL IL256995A patent/IL256995A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3328431A1 (en) | 2018-06-06 |
| CN108025077A (zh) | 2018-05-11 |
| US20180221299A1 (en) | 2018-08-09 |
| AR105533A1 (es) | 2017-10-11 |
| SG10201913254RA (en) | 2020-03-30 |
| MA42521A (fr) | 2018-06-06 |
| GB201513441D0 (en) | 2015-09-16 |
| KR20180035859A (ko) | 2018-04-06 |
| JP2018528175A (ja) | 2018-09-27 |
| WO2017017452A1 (en) | 2017-02-02 |
| MX2018001318A (es) | 2018-08-15 |
| IL256995A (en) | 2018-03-29 |
| AU2016298761A1 (en) | 2018-02-15 |
| CA2994103A1 (en) | 2017-02-02 |
| TW201713340A (zh) | 2017-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385872B (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer | |
| BR112018069789A2 (pt) | medicamento obtido pela combinação do agonista de fxr e arb | |
| BR112016021654A2 (pt) | Sistema para determinar a condição física de uma usuária, dispositivo, e, método para determinar uma condição física de uma usuária | |
| MX2018001006A (es) | Composicion farmaceutica que comprende un vector adenoviral. | |
| MY195474A (en) | Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1) | |
| BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
| BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
| BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
| BR112014026072A2 (pt) | método para medir atenção | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| BR112017014361A2 (pt) | métodos para aperfeiçoamento de terapia celular | |
| AU2018272076A1 (en) | Products and methods for therapeutic administration of microorganisms to non-human animals | |
| BR112018003232A2 (pt) | terapias de combinação para tratamento de câncer | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MY187050A (en) | Cancer cell-specific antibody, anticancer agent, and cancer testing method | |
| BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
| BR112017012337A2 (pt) | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. | |
| BR112015023481A2 (pt) | composição de lipossoma de liberação controlada de fármaco | |
| CL2016000379A1 (es) | Composiciones y métodos terapéuticos para reducción acelerada de plagas | |
| BR112018068129A2 (pt) | método para tratamento de um indivíduo que tem ou está sob risco de câncer. | |
| BR112017002265A2 (pt) | método para monitoramento da deglutição | |
| BR112018071696A2 (pt) | conjunto de cânula e de agulha | |
| BR112016008901A2 (pt) | Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor. | |
| BR112018014069A2 (pt) | uso de uma dieta de reforço e imitação de jejum, uso de uma dieta de reforço e imitação de jejum com um agente quimioterápico, e pacote de dieta. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2630 DE 01-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |